PLoS One by Roca-Feltrer, Arantxa et al.
RESEARCH ARTICLE
Field Trial Evaluation of the Performances
of Point-of-Care Tests for Screening G6PD
Deficiency in Cambodia
Arantxa Roca-Feltrer1, Nimol Khim2, Saorin Kim2, Sophy Chy2, Lydie Canier2,
Alexandra Kerleguer3, Pety Tor3, Char Meng Chuor4, Sim Kheng4,
Sovannaroth Siv4, Patrick S. Kachur5, Walter R. J. Taylor4,6, Jimee Hwang7,
Didier Menard2*
1. Malaria Consortium, Phnom Penh, Cambodia, 2. Malaria Molecular Epidemiology Unit, Institut Pasteur in
Cambodia, Phnom Penh, Cambodia, 3. Medical Laboratory, Institut Pasteur in Cambodia, Phnom Penh,
Cambodia, 4. National Center for Parasitology, Entomology and Malaria Control (CNM), Phnom Penh,
Cambodia, 5. U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 6.
Centre de Me´decine Humanitaire, Hoˆpitaux Universitaires de Gene`ve, Geneva, Switzerland, 7. Global Health
Group, University of California San Francisco, San Francisco, California, United States of America
*dmenard@pasteur-kh.org
Abstract
Background: User-friendly, accurate, point-of-care rapid tests to detect glucose-6-
phosphate dehydrogenase deficiency (G6PDd) are urgently needed at peripheral
level to safely recommend primaquine for malaria elimination.
Methods: The CareStart G6PD RDT (AccessBio, New Jersey, USA), a novel rapid
diagnostic test and the most commonly used test, the fluorescent spot test (FST)
were assessed against the quantitatively measured G6PD enzyme activity for
detecting G6PDd. Subjects were healthy males and non-pregnant females aged 18
years or older residing in six villages in Pailin Province, western Cambodia.
Findings: Of the 938 subjects recruited, 74 (7.9%) were severe and moderately
severe G6PD deficient (enzyme activity ,30%), mostly in male population;
population median G6PD activity was 12.0 UI/g Hb. The performances of the
CareStart G6PD RDT and the FST, according to different cut-off values used to
define G6PDd were very similar. For the detection of severe and moderately severe
G6PDd (enzyme activity ,30%, ,3.6 UI/g Hb) in males and females, sensitivity
and negative (normal status) predictive value were 100% for both point-of-care
tools. When the G6PDd cut-off value increased (from ,40% to ,60%), the
sensitivity for both PoCs decreased: 93.3% to 71.7% (CareStart G6PD RDT,
p51026) and 95.5% to 73.2% (FST, p51026) while the specificity for both PoCs
remained similar: 97.4% to 98.3% (CareStart G6PD RDT, p50.23) and 98.7% to
99.6% (FST, p50.06). The cut-off values for classifying individuals as normal were
4.0 UI/g Hb and 4.3 UI/g Hb for the CareStart G6PD RDTand the FST, respectively.
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Conclusions: The CareStart G6PD RDT reliably detected moderate and severe
G6PD deficient individuals (enzyme activity ,30%), suggesting that this novel
point-of-care is a promising tool for tailoring appropriate primaquine treatment for
malaria elimination by excluding individuals with severe G6PDd for primaquine
treatment.
Introduction
Primaquine (PQ), an 8-aminoquinoline, is the only available and effective drug
both to block P. falciparum transmission by killing mature gametocytes and to
prevent relapses of the persistent liver stage of P. vivax [1]. Recently, the World
Health Organization (WHO) has recommended, without prior G6PDd testing,
the routine addition of single, low-dose PQ (0.25 mg base/kg) as a gametocy-
tocide for P. falciparum infected patients, especially in areas of artemisinin
resistance [2], reassuring countries including Cambodia who have been reluctant
to adopt this policy without additional safety data. Currently, the main limitation
to the use of primaquine, for the radical cure of P. vivax or P. ovale malaria, is the
risk of haemolysis in patients who are glucose 6-phosphate dehydrogenase
(G6PD) deficient [1, 2]. High doses of PQ are rarely used in malaria endemic
countries mainly due to concerns of potentially fatal. Cambodia does not use PQ
as antirelapse treatment for vivax malaria because the high dose involved (30 mg
base daily) would cause significant haemolytic toxicity if given wrongly to G6PDd
patients [3–6]. Thus, the availability of an inexpensive point-of-care (PoC) test
could have tremendous impact on vivax elimination.
G6PDd is an X-linked, hereditary genetic defect due to mutations in the
glucose-6-phosphate dehydrogenase gene, which cause functional variants with
many biochemical/clinical phenotypes [7]. G6PD, the key enzyme in the oxidative
pentose phosphate pathway, converts nicotinamide adenine dinucleotide
phosphate (NADP) into its reduced form, NADPH. NADPH is essential for
protecting erythrocytes against oxidative stress, by reduction of glutathione
disulfide. G6PDd causes increased susceptibility of erythrocytes to reactive oxygen
species that can lead to hemolytic anemia [7]. Drugs such as PQ and Dapsone,
fava beans and infections can induce hemolytic anemia in G6PD-deficient
individuals [8]. In Cambodia, severe and moderate G6PDd are frequent (14.0%)
[9–12], higher in western (15.3%) compared to eastern populations (8.9%) [11].
ViangChan is the most common variant (WHO class II variant), accounting for
more than 90% of G6PDd cases. Its median G6PD enzyme activity is 0.8 UI/g Hb,
representing 0.7% of the population [11, 12].
G6PDd can be detected reliably in homozygous women and hemizygous males
with a number of tests. In heterozygous women, diagnosing G6PDd is more
difficult, and a large part of this group is usually missed by the standard tests [13].
Indeed, heterozygote females with mixed G6PD normal and deficient red cells,
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display varying levels of enzyme deficiency due to the partial inactivation of one X
chromosome, a phenomenon known as lyonisation [14]. To date, the ‘gold
standard’ diagnostic method of G6PDd is based on the estimation of enzyme
activity, by quantitative spectrophotometric analysis of the rate of NADPH
production from NADP+ [7, 15]. For rapid population screening and for guiding
case management, several semi-quantitative methods are in use, [16–21] but most
of them, including the most commonly used test, the fluorescent spot test (FST),
are costly, time-consuming, and requires additional equipment and specified
storage conditions, thus, limiting its use in the field [22, 23].
In 2011, a rapid diagnostic test (RDT)-format test (CareStart, first generation
G6PDd screening test, Access Bio, New Jersey, USA) was evaluated by comparing
its performance to measure G6PD enzyme activity [12]. Its sensitivity and
specificity were estimated to be 68% (66/97) and 100% (806/806), respectively.
Although its detection threshold was noted to be 2.7 UI/g Hb, well within the
range of moderate and severe enzyme deficiencies, thirteen subjects (1.4%, 12
males and 1 female) with G6PD enzyme activities below 2.0 UI/g Hb were falsely
classified as normal. As these patients would potentially have received PQ, they
would have been at risk of hemolysis. Recently, a novel (third generation)
CareStart G6PD RDT has been recently developed by the same manufacturer.
In the study presented, here, we assessed under field conditions, in a
population-based cross- sectional survey, this novel RDT-format test against the
G6PD quantitative assay (‘gold standard’) and the FST (‘clinical standard’), as a
potential alternative tool to guide PQ treatment for the radical cure of P. vivax.
Methods
Study site and population
The study took place in Pailin Province, western Cambodia, area with high rates
of G6PDd (,18%) [11] in six villages (Andong Buon, Bar Yakha, Krachab
Kroam, Oh Preus, Pang Roluem and Prey MangKol). The inclusion criteria were
individuals aged $ 18 years who were competent to give informed consent.
Pregnant and lactating women were excluded. The sample size was calculated
using the precision method to observe an expected sensitivity and specificity of
$90% with a 5% precision. Assuming a 15% G6PD prevalence,.900 participants
needed to be recruited to obtain an expected number .135 G6PDd subjects.
Field procedures and sample collection
In the selected villages, all inhabitants providing informed consent were included
in the study, as previously performed [12]. After obtaining informed consent, a
brief questionnaire was completed and the axillary temperature was recorded.
Individuals with $ 37.5 C˚ were tested for malaria using a RDT (G0131, CareStart
Malaria HRP2/pLDH, Pf/PAN, Access Bio, New Jersey, USA) and treated with
Duo-Cotecxin (dihydroartemisinin plus piperaquine combination, Zhejiang
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Holley Nanhu, Pharamaceutical Co. Ltd, Jiaxing City, China) as recommended in
the Cambodian National Treatment Guidelines, if testing was positive.
Blood was collected both by finger prick (25 mL) and by venous puncture
(2 mL in an EDTA tube). The capillary blood sample was used to perform the
CareStart G6PD RDT (Access Bio, New Jersey, USA) and the FST (ref 203-A,
Trinity Biotech, St. Louis, USA), according to manufacturers’ instructions. Briefly,
for the CareStart G6PD RDT, two microliters of blood were collected using the
lancet provided in the kit and added into the sample well and two drops of buffer
into the buffer well. Test results were read visually after 10 minutes (using a
watch). Samples with normal G6PD activity produce a distinct purple color
background in the result window while no color change was observed at the test
read time for samples with deficient G6PD activity. Samples with a pale purple
color background were conservatively classified as deficient. For both PoC,
readings were made by two independent blinded researchers. When discordances
were recorded between the two readers (result reported as normal by one reader
and deficient by the second reader), the final decision was to consider the
individual as deficient. Venous blood samples were stored at 4 C˚ in cool boxes
and transported to Phnom Penh within 24 hours. Before their use in the field, the
validity of both PoCs was monitored by three levels of G6PD controls (deficient,
intermediate and normal, Trinity Biotech, St. Louis, USA).
Laboratory procedures
The cells blood count (CBC), the determination of the G6PD enzyme activity and
the capillary Hb electrophoresis was done as previously described [11]. On a
random sub-set of samples, capillary and venous blood were assessed for
concordance on the CareStart G6PD RDT (n548) and the FST (n538). Venous
blood and white cell depleted blood using a CF11 column [24] was also assessed
for concordance (n531 for CareStart G6PD RDT and n538 for FST) to explore if
leukocytes and platelets which may be rich in G6PD enzyme cause some
interference in the assays, as has been already observed [25].
DNA was extracted from red blood cells and the buffy coat in all individuals
with , 60% of normal G6PD enzyme activity using the QIAamp DNA Blood
Mini Kit (Qiagen, Courtaboeuf, France), according to the manufacturer’s
instructions. They were used to perform the detection of malaria parasites by PCR
[26] and to detect mutations in the glucose-6-phosphate dehydrogenase gene [12],
respectively.
G6PDd detection and haemoglobinopathies classification
The normal value of G6PD enzymatic activity in Cambodian adults was defined
by using the adjusted median (100% G6PD activity), as previously described [27].
The adjusted median value was determined from the G6PD enzyme activity values
measured in the male population, after excluding males with severe G6PD
deficiency (G6PD enzyme activity , 10% normal). G6PDd was defined as a
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percentage of normal G6PD activity and individuals were classified according to
different cut off values of residual activity (,10%, ,20%, ,30%, ,40%, ,50%,
,60%, $60%).
Normal haemoglobin profile and haemoglobinopathies were defined as
previously described [11].
Data management and statistical analyses
Data were recorded on a case reporting form (CRF), double-entered into an
electronic database and analyzed using MedCalc software (version 9.1.0.1;
Mariakerke, Belgium).
According to the different cut-offs used to define G6PDd and using the
quantitative G6PD assay as the gold standard, classical diagnostic test
performance measures were determined: Sensitivity (Se), Specificity (Sp),
Deficient/Positive Predictive Value (PPV) and Normal/Negative Predictive Value
(NPV) [28]. Test performances of PoCs were also compared between samples
collected from capillary/venous blood, and from capillary/white cell depleted
venous blood.
The mean, median, standard deviation and ranges were determined for all
G6PD enzyme activity values by gender and type of blood sample (capillary,
venous, white cell depleted venous). The ANOVA test, the Mann-Whitney U test
and the Student’s t test were used for comparisons of continuous variables. For
categorical variables, Chi-squared or Fisher’s exact tests were used to assess
significant differences in proportions. Odds ratios were used to compare the
relative odds of the occurrence of G6PDd, given exposure to the variable of
interest [29]. Comparisons showing p-value , 0.05 was considered to be
statistically significant.
Ethical considerations
The study protocol was reviewed and approved by the National Ethics Committee
for Health Research of the Ministry of Health of Cambodia (approval number 275
NECHR). The U.S. Centers for Disease Control and Prevention Institutional
Review Board reviewed and granted non-engaged status. Informed written
consent was provided by all individuals before inclusion in the study and all
investigations were conducted according to the principles expressed in the
Declaration of Helsinki. Results for each patient (according to the quantitative
G6PD activity test) were given to the local Ministry of Health staff of Pailin
province involved in the study.
Results
Study population and distribution of the G6PD enzymatic activity
From February-May 2013, 938 subjects were enrolled from six villages in Pailin
Province. The male/female ratio was 451/487 (0.93) and age ranged from 18 to 75
G6PD Deficiency Point-of-Care Tests
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years old (median532 years, IQR 24–48 years) (Table 1). All participants declared
they were ethnic Khmer. Approximately, one third had an abnormal haemoglobin
electrophoresis profile and 13.6% (127/938) had ,60% of normal enzyme
activity, according to the quantitative G6PD activity test. No significant
differences were observed between villages, except for age, white and red blood
cells counts and haemoglobin electrophoresis profiles. Among 19 febrile patients,
3 were found positive by RDT and treated with Duo-Cotecxin (Table 1). The
proportion of positive parasite carriers detected by PCR was 1.9% (14/750). P.
vivax was the most prevalent species (12/14, 86%). Only one individual with P.
vivax infection had a 30–40% of normal G6PD enzyme activity. The other malaria
cases were G6PD normal including two falciparum malaria cases. No significant
differences were observed in G6PD enzyme activity median between malaria-
infected and non-infected individuals (12.2 vs. 11.7 UI/g Hb, p50.70, Mann-
Whitney U test).
Reference range of G6PD enzymatic activity, prevalence of G6PDd
and G6PD variants
G6PD enzymatic activity values ranged from 0.3 to 45.9 UI/g Hb (Fig. 1, Table 2).
No significant difference for median was observed between gender (p50.31,
Mann-Whitney U test). Based on the adjusted male median, 100% G6PD activity
was estimated to be 12.0 UI/g Hb and cut-off values were defined as presented in
Table 3. The prevalence of G6PDd was as follows: 56/938 (6.0%) with ,10% of
normal G6PD enzyme activity; 68/938 (7.2%) with ,20% of normal G6PD
enzyme activity; 74/938 (7.9%) with ,30% of normal G6PD enzyme activity; 89/
938 (9.5%) with ,40% of normal G6PD enzyme activity; 107/938 (11.4%) with
,50% of normal G6PD enzyme activity; 127/938 (13.5%) with ,60% of normal
G6PD enzyme activity.
Males were more frequently severely deficient: ,10% of normal G6PD enzyme
activity (48/451 in males vs. 8/487 in females, OR56.4, 95% CI: 3.0–13.8,
p,1027, Fisher’s exact test), ,20% of normal G6PD enzyme activity (57/451 in
males vs. 11/487 in females, OR55.6, 95% CI: 2.9–10.8, p,1028, Fisher’s exact
test), ,30% of normal G6PD enzyme activity (59/451 in males vs. 15/487 in
females, OR54.2, 95% CI: 2.4–7.6, p,1027, Fisher’s exact test) and ,40% of
normal G6PD enzyme activity (59/451 in males vs. 30/487 in females, OR52.1,
95% CI: 1.3–3.4, p,1023, Fisher’s exact test).
Among the 127 G6PDd individuals (,60% of normal G6PD enzyme activity),
sequencing of the G6PD gene detected 6 G6PD variants (Table 4). The most
prevalent was G6PD-ViangChan (117/127, 92.0%,) followed by G6PD-Canton (4/
127, 3.2%), G6PD-CoImbra and G6PD-Mediteranean (2/127, 1.6% and 2/127,
1.6%, respectively) and G6PD Chinese-5 and G6PD-Mahidol (1/127, 0.8%, and 1/
127, 0.8%, respectively).
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Fig. 1. Distribution of the G6PD enzymatic activity (UI/g Hb) values according to gender, of 938 Cambodians adults residing in six villages of the
Pailin province, Cambodia, 2013. (Panel A: Total population, Panel B: Male population and Panel C: Female population).
doi:10.1371/journal.pone.0116143.g001
Table 2. Reference values of the G6PD enzymatic activity profile for the study population, Pailin, Cambodia, 2013.
Reference values Female Male Adjusted male*
Number of cases 487 451 392
Mean (95% CI) UI/g Hb 11.8 (11.4–12.2) 11.2 (10.7–11.7) 12.8 (12.4–13.1)
SD 4.4 5.1 3.3
Median (95% CI) UI/g Hb 11.9 11.7 12.0
IQR 9.7–14.0 10.2–13.4 10.6–13.6
Range 0.5–45.9 0.3–42.5 7.4–42.5
* Adjusted median (100% G6PD activity): an adjusted median value is calculated for which males with severe G6PD deficiency (activity less than 10%
normal) have been excluded. This is accomplished by:1. Exclusion of all males with G6PD activity equal to or less than 10% of the male median; 2.
Determination of a new median G6PD activity [27].
doi:10.1371/journal.pone.0116143.t002
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Performances of PoC tests to detect G6PDd
Defining G6PDd as G6PD activity ,60% (n5127), the sensitivity, specificity,
PPV and NPV for the CareStart G6PD RDT were 71.7% (91/127), 98.3% (797/
811), 86.7% (91/105) and 95.7% (797/833). Corresponding FST values were:
73.3% (93/127), 99.6% (808/811), 96.9% (93/96) and 96.0% (808/842).
The performances of the CareStart G6PD RDT and the FST, according to the
cut-off values used to define G6PDd were very similar (Table 3). No false normal
results were observed in G6PD deficient individuals defined with a cut-off value
,30% (,3.6 UI/g Hb). When the G6PDd cut-off value increased (from ,40% to
,60%), the sensitivity for both PoCs decreased: 93.3% to 71.7% (CareStart G6PD
RDT, p51026, Fisher’s exact test) and 95.5% to 73.2% (FST, p51026, Fisher’s
exact test) while the specificity for both PoCs remained similar: 97.4% to 98.3%
(CareStart G6PD RDT, p50.23, Fisher’s exact test) and 98.7% to 99.6% (FST,
p50.06, Fisher’s exact test). The cut-off values for classifying individuals as
normal were 4.0 UI/g Hb and 4.3 UI/g Hb for the CareStart G6PD RDT and the
FST, respectively (Fig. 2).
Table 4. G6PD enzymatic activity by G6PD-variants in hemizygous males, homozygous and heterozygous females (n5127), Pailin, Cambodia, 2013.
Variants Exon Mutation
G6PD enzyme
activity (UI/g Hb)
Hemizygous
male
Homozygous
female
Heterozygous
female Total
ViangChan 9 871G.A, 1311C.T,
IVS11 nt93T.C
N 55 15 49 117
(92.1%)
Range 0.3–3.2 0.5–3.2 3.9–7.1
Mean (95% CI) 1.0 (0.8–1.1) 1.5 (1.0–2.0) 5.6 (5.3–5.9)
Median (IQR) 0.9 (0.6–1.2) 1.2 (0.8–2.4) 5.6 (4.6–6.4)
Mediterranean 6 563C.T N 2 0 0 2 (1.6%)
Range - - -
Mean (95% CI) 0.4 - -
Median (IQR) 0.4 - -
Canton 12 1376G.T N 1 0 3 4 (3.1%)
Range - - 5.5–7.1
Mean (95% CI) 0.8 - 6.3 (4.3–8.3)
Median (IQR) 0.8 - 6.4 (5.7–6.9)
CoImbra 6 592C.T N 1 0 1 2 (1.6%)
Range - - -
Mean (95% CI) 0.5 - 4.3
Median (IQR) 0.5 - 4.3
Mahidol 6 487G.A N 0 0 1 1 (0.8%)
Range - - -
Mean (95% CI) - - 4.7
Median (IQR) - - 4.7
Chinese-5 9 1024C.T N 0 0 1 1 (0.8%
Range - - -
Mean (95% CI) - - 4.5
Median (IQR) - - 4.5
doi:10.1371/journal.pone.0116143.t004
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In the male population, the CareStart G6PD RDT had a 100% sensitivity and
NPV, for detecting G6PDd, regardless the cut-off values used to define G6PDd.
Only five males (5/392, 1.3%) with a G6PD enzyme activity $60% were
misclassified as G6PD deficient. Amongst females, the CareStart G6PD RDT had a
100% sensitivity and NPV at G6PD enzyme activities ,30% (,3.6 UI/g Hb).
Thereafter, the sensitivity declined markedly with increasing G6PD enzyme
activity. The proportion of females classified as G6PD normal increased with the
cut-off values: 6/15 (40%) at threshold ,40% (,4.8 UI/g Hb); 13/18 (72%),
,50% (,6.0 I/g Hb); 17/20 (85%), ,60% (,7.2 UI/g Hb) and 410/419 (97.8%),
$60% ($ 7.2 UI/g Hb) (Fig. 2 and Table 5).
Impact of the blood source (capillary versus venous blood) and the
white blood cells (WBC)
The results of the CareStart G6PD RDT (n548) performed in parallel by using
capillary and venous blood were concordant in 47/48 (98.0%): 24 capillary/venous
blood samples and 23 capillary/venous blood samples were both classified as
G6PD deficient and G6PD normal, respectively. The finger prick sample of one
female (aged 34 years, G6PD enzyme activity 6.4 UI/g Hb, ViangChan variant)
provided a G6PD normal result while the venous blood a G6PD deficient result.
Among the 38 individuals tested in parallel with the FST all samples were
concordant (100%, 20 deficient and 18 normal).
Fig. 2. Distribution of the G6PD enzymatic activity (UI/g Hb) values by gender according to point-of-
care tests results in 938 Cambodians adults, Cambodia, 2013. CareStart G6PD RDT: green circle (G6PD-
normal) and red circle (G6PD-deficient); fluorescent spot test: green triangle (G6PD-normal) and red triangle
(G6PD-deficient). The cut-off values (from 10% to 60%) used to define G6PDd are presented as pale blue
dash lines.
doi:10.1371/journal.pone.0116143.g002
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The results of the CareStart G6PD RDT (n531) performed in parallel by using
fresh venous blood before and after WBC removal were concordant in 30/31
(97.0%, 14 normal and 16 deficient). For one female (aged 24 years, G6PD
enzyme activity 8.1 UI/g Hb, WBC 4.6 61023/mm3), her fresh venous blood
provided a G6PD normal result while her venous blood after WBC removal, a
G6PD deficient result. Among the 38 individuals tested in parallel with the FST,
all samples were concordant (100%, 20 deficient and 18 normal).
Discussion
Results from this study provide strong evidence on the ability of the CareStart
G6PD RDT to detect reliably G6PD deficient individuals in males and in females
with enzyme activity levels ,30% of normal G6PD enzyme activity (,3.6 UI/g
Hb), with performance properties comparable to the commonly used FST. The
CareStart G6PD RDT therefore represents an excellent and inexpensive (cost/test
, $1.50 US) alternative PoC to the FST especially considering FST’s costs, time to
result, additional equipment requirements and specified storage conditions
[22, 23]. Even, the sensitivity of the CareStart G6PD RDT for diagnosing G6PDd
defined as ,60% of normal G6PD enzyme activity) was modest (,70%), the
CareStart G6PD RDT was 100% sensitive and specific for diagnosing all severe,
and moderately severe G6PDd (,30% enzyme activity). In this group, no false
normal was recorded. This is a considerable improvement on the previous
generation test, which demonstrated lower sensitivity and unacceptably high risk
of diagnosing false ‘normal’ status to several severe class II variants [12].
The reason for testing for patients for G6PDd is to identify those who may be at
risk of PQ induced haemolysis. This risk is greatest in those with lower G6PD
enzyme activities who will receive PQ for radical cure [3, 30–32]. The current
recommended dose for vivax (‘Chesson’ strain) is 0.5 mg/kg (30 mg in an adult)
daily for 14 days in G6PD normal individuals. Data from G6PD deficient
Cambodian airmen showed that 15 mg of daily primaquine resulted in mean fall
in Hb of 3 g/dl on Day 7. Their G6PD activities were generally between 4–11% of
normal; thus, most had severe class II G6PDd [4]. This fall would be higher in
vivax infected patients treated with the same dose of PQ. G6PDd vivax infected
patients are also at risk of haemolysis if they receive the recommended, 0.75 mg/
kg weekly dose of primaquine for 8 doses. Data from a recently conducted safety
Plasmodium vivax study on primaquine (Kheng S, Cambodian National Malaria
Control Programme, unpublished data) suggest weekly primaquine (0.75 mg/kg)
could be used under medical supervision in G6PDd patients.
Although, the evidence for the reduction of mosquito infectivity using the
newly recommended low dose primaquine (0.25 mg/kg) in falciparum infected
patients for transmission blocking have been recently reviewed by White and
colleagues [2], data on primaquine safety in G6PDd individuals with falciparum
malaria remain rare. There is a broad consensus on the needed to conduct
prospective studies to confirm the safety of a single dose of primaquine as a
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gametocytocide together with ACT especially in Cambodia where artemisinin
resistant falciparum parasites are circulating [33]. To address this question, a
study is planned in Cambodia to evaluate its safety and to explore the applicability
of the CareStart G6PD RDT (if necessary) as a PoC diagnostic to identify those
patients who might suffer from significant haemolysis. For the CareStart G6PD
RDT to efficiently work in real-life conditions, it was also critical to assess whether
capillary samples performed equally well compared to the venous blood samples,
as capillary samples are taken for slide preparation and malaria RDTs by health
workers. Concordances between both capillary/venous blood samples were
excellent. Only one discordance, with venous blood was found in a subject whose
G6PD activity was 6.4 UI/g Hb (,53% of normal G6PD enzyme activity).
Similarly, only one white cell depleted venous sample gave a discordant result.
Although the performance of the CareStart G6PD RDT was assessed in the
field, it was conducted by a research team. Therefore, there is a need to evaluate
the test characteristics of the CareStart G6PD RDT by the users of this PoC, such
as health facility staff and village malaria workers (VMWs). They are the malaria
elimination ‘‘front line’’ in Cambodia and shoulder the responsibility for
diagnosis, treatment, follow up and data recording. To accelerate the roll out of
the CareStart G6PD RDT use and PQ in Cambodia, further evaluations have
already been initiated to assess the operational challenges and programmatic
usefulness of the tests when implemented by health workers in the field.
Supporting Information
S1 Data. Data base listing all variables assessed in the study by individual.
doi:10.1371/journal.pone.0116143.s001 (XLSX)
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